CyBio (Germany)
CyBio AG manufacture a range of products for high throughput screening laboratories including;
Pipetting
 | CyBi-SmartWell Low cost systems for 3 x 96 well plate transfers, dispensing. 5 to 250microlitre capacity |
| CyBi-Well. A modular multiple plate pipetting station for rapid plate duplication. |
| CyBi-Disk. & FlexDeck Fully automated modular pipettor for up to 10 x 96,384 or 1536 well plates. More plate capacity with optional FlexDeck plate feeder /stacker |
| Cy-Bi Dilus Pro. 8 channel pipetting station. 4 or 5 plate version or 10 plate circular platform |
Dispensing
| Cy-Bi Drop. Accurate and fast dosing for 96, 384 and 1536 well plates down to 1 microlitre per well |
| Cy-Bi NanoJet. Accurate and fast dosing for 96, 384 and 1536 well plates down to 50 nano-litre per well |
Readers
| Cy-Bi Lumax |
Other Automation Products
| Cy-Bi Robospense. Complete self contained dispensing systemsfor 1536 well plates |
| Cy-Bi Ways Linear Transport system. Complete automation systems for microtitre plate handling |
| Cy-Bi Screen. Harmonized High Throughput Screening Systems comprising, dispensing, incubation, reading and plate housing |
| Cy-Bi Replicator |
| CyBio Software. Control software for Cy-Bio products |
In a remarkably short time, research in the pharmaceutical industry has transformed its entire modus operandi. Drug discovery has been a process plagued with throughput bottlenecks at each stage due to limitations of labor, time, and money. But pressures to find new lead structures created a strong impetus to eliminate bottlenecks. The answer was industrialized research, and CyBio was one of the first to lead the transformation.
A trigger product for the industry was an accurate parallel pipettor developed by CyBio. It enabled the processing of assays miniaturized to run on microplates. CyBio extended that success with
computer-controlled systems which sparked the development of devices that could be integrated and controlled by software. Wide industry acceptance spurred CyBio, in conjunction with top laboratories, to systematically identify then eliminate bottlenecks in every stage of drug discovery.
CyBio enabled the miniaturization of biological assays to microliter volumes without sacrificing accuracy, precision and reliability. Freed from tedious manual processes, researchers worldwide now have the power to manage hundreds of assays in an area the size of their hand.
Identifying lead compounds can not be reduced to a single optimal strategy. This fact makes designing your drug discovery laboratory a seemingly difficult act of balancing flexibility and reliability. With CyBio products and services, you have the confidence knowing your investment today will not become a liability tomorrow.
Obtaining information for making crucial decisions requires more than simply generating data points. Your drug discovery process must go beyond a throughput system to be a biological analysis system. The high standards of analytics coupled with CyBio's renowned high-throughput capability builds your proficiency in identifying new lead structures and delivers more valuable results to your downstream drug discovery stages. Your desire to continually increase the quality and value of drug discovery results is the same long-term approach CyBio applies to building biological analysis tools.
Because drug discovery does not have a single best strategy, CyBio's machines are constructed with a potential for scalability and integration to adapt to your changing research needs. After fifteen years in the business of maximizing the productivity of drug discovery research, CyBio has the experience and the vision to help you meet your objectives over the long term.
CyBio knows past improvements in productivity are only an indication of future advances. The industrialization of research promises to deliver millions of new test substances to test against hundreds of new targets. Assay size and research timelines will continue to shrink while the demand for decisive data will reach into the earliest stages of research. CyBio welcomes this reality.
Laboratories miniaturize assays to lower costs, examine larger libraries with faster turnaround and conserve precious compounds. But miniaturization is more than simply reducing volume - it hinges upon machine accuracy and precision. Consider the 100-fold reduction in volume when an assay is reduced from 200p1 to 2pl (e.g. 96-well versus 1536-well plates). Correspondingly, it requires a 100-fold increase in machine quality. CyBio standards for machine quality (accuracy and precision) are set high to meet your current and future needs.
Multiply millions of new compounds by hundreds of new targets and the requirement for more throughput becomes obvious. Not only are CyBio machines engineered to exceptional quality standards, but they deliver reliable throughput. CyBio machines surpass the traditional trade-offs of quality and throughput. The benefit for you is a new level of drug discovery productivity.
For more information click on the relevant icon at left or contact B.E.S.T or
click HERE to be redirected to the CyBio
site for more specific information.
